Your browser is no longer supported. Please, upgrade your browser.
Anavex Life Sciences Corp.
Index- P/E- EPS (ttm)-0.45 Insider Own3.48% Shs Outstand70.03M Perf Week-2.03%
Market Cap793.77M Forward P/E- EPS next Y-0.60 Insider Trans-5.48% Shs Float67.16M Perf Month-8.58%
Income-27.50M PEG- EPS next Q-0.14 Inst Own21.40% Short Float10.27% Perf Quarter-16.12%
Sales- P/S- EPS this Y16.00% Inst Trans5.68% Short Ratio4.90 Perf Half Y111.05%
Book/sh0.72 P/B15.39 EPS next Y-7.10% ROA-72.70% Target Price18.80 Perf Year217.48%
Cash/sh- P/C- EPS next 5Y- ROE-89.60% 52W Range3.42 - 28.70 Perf YTD105.19%
Dividend- P/FCF- EPS past 5Y7.10% ROI- 52W High-61.39% Beta0.57
Dividend %- Quick Ratio6.80 Sales past 5Y- Gross Margin- 52W Low223.98% ATR0.77
Employees20 Current Ratio6.80 Sales Q/Q- Oper. Margin- RSI (14)41.87 Volatility8.46% 6.19%
OptionableYes Debt/Eq0.00 EPS Q/Q-1.50% Profit Margin- Rel Volume0.70 Prev Close10.16
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume1.41M Price11.08
Recom1.70 SMA20-4.79% SMA50-15.59% SMA20041.37% Volume980,332 Change9.06%
Dec-16-20Reiterated H.C. Wainwright Buy $14 → $17
Sep-28-20Initiated Ladenburg Thalmann Buy $12
Feb-27-20Initiated Cantor Fitzgerald Overweight
Jun-18-19Initiated Janney Buy
May-16-18Resumed Maxim Group Buy $5 → $7
Mar-08-18Initiated ROTH Capital Buy $6
Feb-13-18Reiterated Maxim Group Buy $14 → $5
Sep-29-17Resumed Noble Financial Buy $15
Feb-07-17Initiated Noble Financial Buy $16
Mar-29-16Initiated FBR Capital Outperform $10
May-14-21 01:30PM  
May-13-21 02:30PM  
May-11-21 08:37AM  
May-07-21 07:00AM  
May-06-21 07:00AM  
May-05-21 07:00AM  
Apr-26-21 07:00AM  
Apr-22-21 12:05PM  
Apr-12-21 07:00AM  
Apr-08-21 07:00AM  
Apr-07-21 07:00AM  
Mar-31-21 07:00AM  
Mar-16-21 07:00AM  
Mar-12-21 08:00AM  
Mar-11-21 07:00AM  
Mar-04-21 07:00AM  
Feb-28-21 11:39PM  
Feb-22-21 07:00AM  
Feb-19-21 07:00AM  
Feb-18-21 07:00AM  
Feb-11-21 10:01PM  
Feb-10-21 10:21AM  
Feb-08-21 08:22AM  
Feb-05-21 09:15AM  
Feb-04-21 01:54PM  
Feb-03-21 06:40PM  
Feb-01-21 10:28AM  
Jan-28-21 10:12AM  
Jan-27-21 11:13AM  
Jan-11-21 07:00AM  
Jan-06-21 07:00AM  
Jan-04-21 09:30AM  
Dec-31-20 12:00PM  
Dec-28-20 02:30PM  
Dec-22-20 07:00AM  
Dec-21-20 07:00AM  
Dec-15-20 05:57PM  
Nov-30-20 07:00AM  
Nov-27-20 10:00AM  
Nov-25-20 07:00AM  
Nov-06-20 10:45AM  
Oct-16-20 08:54AM  
Oct-15-20 03:13PM  
Sep-10-20 07:00AM  
Sep-08-20 07:00AM  
Sep-02-20 07:01AM  
Aug-19-20 07:00AM  
Aug-06-20 07:00AM  
Aug-05-20 04:05PM  
Aug-04-20 07:00AM  
Jul-06-20 07:00AM  
Jul-01-20 07:00AM  
Jun-26-20 12:00PM  
Jun-18-20 11:30AM  
Jun-16-20 07:00AM  
Jun-15-20 12:00PM  
Jun-14-20 09:07PM  
Jun-12-20 09:45AM  
Jun-11-20 06:15PM  
Jun-04-20 07:00AM  
Jun-02-20 11:30AM  
Jun-01-20 07:59AM  
May-21-20 07:00AM  
May-14-20 10:07AM  
May-13-20 12:00PM  
May-07-20 07:00AM  
May-05-20 07:00AM  
Apr-23-20 07:00AM  
Apr-14-20 11:48AM  
Apr-03-20 05:45PM  
Mar-31-20 07:00AM  
Mar-23-20 08:00AM  
Feb-24-20 07:00AM  
Feb-17-20 12:00PM  
Feb-14-20 09:18AM  
Feb-13-20 12:48PM  
Feb-11-20 09:22AM  
Feb-10-20 10:56PM  
Feb-06-20 02:30PM  
Feb-04-20 07:00AM  
Feb-03-20 07:00AM  
Jan-31-20 11:30AM  
Jan-30-20 07:00AM  
Jan-27-20 07:00AM  
Jan-23-20 08:42AM  
Jan-17-20 08:16AM  
Jan-15-20 04:34PM  
Jan-14-20 12:00PM  
Jan-08-20 08:53AM  
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FAVUS ELLIOTDirectorFeb 24Option Exercise3.06145,500445,390145,000Feb 26 09:31 PM
FAVUS ELLIOTDirectorFeb 24Sale12.66145,5001,841,8550Feb 26 09:31 PM
Donhauser Peter D.O.DirectorFeb 19Buy12.671,16514,7601,165Feb 23 01:22 PM